To the Editor:
In a recent issue of CHEST (January 2013), Durmowicz et al 1 highlight the fi nding that despite improvement in both cystic fi brosis (CF) transmembrane conductance regulator (CFTR) and pulmonary function in clinical trials of ivacaftor (recently approved by the US Food and Drug Administration for individuals with CF and the G551D mutation), there does not appear to be a direct correlation between changes in sweat chloride (a measure of CFTR function) and changes in FEV 1 (an established effi cacy measure). They also were unable to identify a minimum threshold for change in sweat chloride that was associated with FEV 1 improvement.
Despite the fi ndings, lack of a linear correlation between the changes in these outcome measures should not diminish the potential utility of sweat chloride for predicting clinical outcomes. Although the data presented failed to show a population level threshold for change in sweat chloride, the absolute sweat chloride concentrations after treatment in the two ivacaftor trials were not assessed. While adult sweat chloride values are highly variable across CF and healthy control subjects, 2 concentrations , 60 mM are typical among individuals without CF, and intermediate values are associated with a more benign clinical course. In reanalysis of the ivacaftor trial data, Seliger et al 3 show that nearly every participant has a resulting sweat chloride Յ 80 mM after 2 weeks of treatment, which does not provide the spectrum of response required to readily establish a linear correlation with another outcome. Thus, correlation between changes in sweat chloride and change in FEV 1 may not fully capture the predictive ability of sweat chloride.
There is no doubt that FEV 1 variability across and within individuals poses a challenge for clinical research in CF. That variability comes from years of infection, infl ammation, and structural damage to the lung and can confound treatment effects. Before a meaningful quantitative relationship between CFTR activity and lung function or other clinical outcomes can be established, more work must be done to better understand the complex collection and interaction of physiologic and clinical measures in CF, particularly across diverse patient populations. The evaluation of younger patient populations with mild disease (and for whom lung function cannot be reliably measured nor acute changes expected) poses a particular challenge and highlights the need for robust pharmacodynamic parameters predictive of clinical response. Further discussions between regulatory agencies, trial sponsors, and community advocates will be necessary for monitoring the evolution of biomarkers in the regulatory approval process to ensure availability of beneficial and safe therapies. 
